Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

OBJECTIVE: The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab (an IL-17A antagonist) treatment in PsA patients. METHODS: In a phase III study, patients naïve to biologic treatment were randomized to placebo, adalimumab 40 mg every 2 weeks (ADA; active reference) or ixekiz...

詳細記述

保存先:
書誌詳細
出版年:Rheumatology (Oxford)
主要な著者: Chandran, Vinod, van der Heijde, Désirée, Fleischmann, Roy M, Lespessailles, Eric, Helliwell, Philip S, Kameda, Hideto, Burgos-Vargas, Ruben, Erickson, Janelle S, Rathmann, Suchitrita S, Sprabery, Aubrey Trevelin, Birt, Julie A, Shuler, Catherine L, Gallo, Gaia
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2020
主題:
Clinical Science
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7516094/
https://ncbi.nlm.nih.gov/pubmed/32031665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kez684
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料